HeartCore Enterprises Bolsa (NASDAQ: HTCR)

Últimas noticias sobre HeartCore Enterprises (NASDAQ:HTCR) Bolsa

HeartCore Enterprises

HeartCore Enterprises Inc is a software development company. It provides software through two business units. The first business unit includes a customer experience management business that has been in existence for 12 years. The customer experience management platform includes marketing, sales, service and content management systems, as well as other tools and integrations, that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, its DX division, is a digital transformation business that provides customers with robotics process automation, process mining and task mining to accelerate the digital transformation of enterprises.

Heartcore Enterprises, Inc. - Common Stock

HeartCore Enterprises Inc

Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.63 by 11.11 percent. This is a 37.25 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $7.36 billion which beat the analyst consensus estimate of $7.08 billion by 4.04 percent. This is a 7.74 percent increase over sales of $6.83 billion the same period last year.

Earnings

Earnings Beats

News

Baker Hughes Q4 2024 Adj EPS $0.70 Beats $0.63 Estimate, Sales $7.36B Beat $7.08B Estimate

Across the recent three months, 4 analysts have shared their insights on AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.25, with a high estimate of $11.00 and a low estimate of $9.50. This current average represents a 2.38% decrease from the previous average price target of $10.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738274475_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive AGNC Investment. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jason Weaver</td>
<td>Jones Trading</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.25</td>
<td>$10.25</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.25</td>
<td>$10.75</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.50</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AGNC Investment. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AGNC Investment compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AGNC Investment's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into AGNC Investment's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AGNC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AGNC Investment analyst ratings.</a>
<h2>Discovering AGNC Investment: A Closer Look</h2>
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
<h3>AGNC Investment: Delving into Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Challenges: AGNC Investment's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -59.04%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 55.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AGNC Investment's ROE stands out, surpassing industry averages. With an impressive ROE of 1.06%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.1%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

AGNC

Assessing AGNC Investment: Insights From 4 Financial Analysts

Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $18.73, a high estimate of $24.00, and a low estimate of $16.00. Witnessing a positive shift, the current average has risen by 19.76% from the previous average price target of $15.64.
<img src="https://www.benzinga.com/files/images/story/2025/1738274465_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Upwork by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kunal Madhukar</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Marvin Fong</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Upwork. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Upwork compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Upwork's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Upwork's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UPWK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Upwork analyst ratings.</a>
<h2>About Upwork</h2>
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to clients.
<h3>Financial Milestones: Upwork's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Upwork displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 10.27%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Upwork's net margin is impressive, surpassing industry averages. With a net margin of 14.32%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Upwork's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.68%, the company showcases effective utilization of assets.
Debt Management: Upwork's debt-to-equity ratio is below the industry average at 0.9, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UPWK

Breaking Down Upwork: 11 Analysts Share Their Views

Ratings for Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $175.75, with a high estimate of $200.00 and a low estimate of $157.00. This upward trend is evident, with the current average reflecting a 2.03% increase from the previous average price target of $172.25.
<img src="https://www.benzinga.com/files/images/story/2025/1738274456_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Crane. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Summerville</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$170.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$157.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Hold</td>
<td>$176.00</td>
<td>$176.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Crane. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Crane compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Crane's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Crane's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Crane analyst ratings.</a>
<h2>Delving into Crane's Background</h2>
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
<h3>Unraveling the Financial Story of Crane</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Crane faced challenges, resulting in a decline of approximately -8.89% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Crane's net margin excels beyond industry benchmarks, reaching 14.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Crane's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.04%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Crane's ROA excels beyond industry benchmarks, reaching 3.07%. This signifies efficient management of assets and strong financial health.
Debt Management: Crane's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.15.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Crane Stands With Analysts

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for BlackLine, revealing an average target of $71.3, a high estimate of $86.00, and a low estimate of $60.00. Witnessing a positive shift, the current average has risen by 9.69% from the previous average price target of $65.00.
<img src="https://www.benzinga.com/files/images/story/2025/1738274443_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive BlackLine is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koji Ikeda</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Buy</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$86.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Chris Quintero</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$51.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BlackLine. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BlackLine compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BlackLine's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into BlackLine's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BlackLine analyst ratings.</a>
<h2>About BlackLine</h2>
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their financial close process including account reconciliations, variance analysis of account balances, journal entry capabilities, and certain types of data matching capabilities. The majority of the revenue of the company is earned in the United States.
<h3>BlackLine's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: BlackLine's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.09%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: BlackLine's net margin is impressive, surpassing industry averages. With a net margin of 10.39%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.97%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): BlackLine's ROA excels beyond industry benchmarks, reaching 0.96%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.49, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 10 Analysts Discuss BlackLine Stock

4 analysts have shared their evaluations of UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $141.5, a high estimate of $156.00, and a low estimate of $128.00. This current average reflects an increase of 8.02% from the previous average price target of $131.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738274429_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of UMB Financial among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$128.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Nathan Race</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$139.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Brian Wilczynski</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$156.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UMB Financial. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UMB Financial compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of UMB Financial's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UMBF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UMB Financial analyst ratings.</a>
<h2>Unveiling the Story Behind UMB Financial</h2>
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking, asset management, and health spending solutions. Its customer base includes commercial, institutional, and personal customers across the United States. The company's banking subsidiaries own and operate banking and wealth-management centers mostly throughout the Midwest and Southwest regions of the U.S. Subsidiaries of the holding company and its lead bank, UMB Bank, include mutual fund and alternative investment services groups, single-purpose companies that deal with brokerage services and insurance, and a registered investment advisory. The bank's revenue is split nearly evenly between interest income and noninterest income.
<h3>UMB Financial's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: UMB Financial's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 8.32%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 30.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): UMB Financial's ROE stands out, surpassing industry averages. With an impressive ROE of 3.43%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.25%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: UMB Financial's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UMBF

A Glimpse Into The Expert Outlook On UMB Financial Through 4 Analysts

Barrington Research analyst James Goss maintains Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) with a Outperform and maintains $30 price target.

Price Target

SIRI

Barrington Research Maintains Outperform on Sirius XM Holdings, Maintains $30 Price Target

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.34% on an annualized basis producing an average annual return of 20.61%. Currently, Alnylam Pharmaceuticals has a market capitalization of $36.14 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 15 years ago, it would be worth $16,726.61 today based on a price of $280.16 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738274415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ALNY

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

8 analysts have shared their evaluations of Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $24.62, along with a high estimate of $39.00 and a low estimate of $16.00. Observing a 15.15% increase, the current average has risen from the previous average price target of $21.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1738274416_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Pacira BioSciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pacira BioSciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pacira BioSciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Pacira BioSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Pacira BioSciences</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Financial Insights: Pacira BioSciences</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Pacira BioSciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 2.83%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Pacira BioSciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -85.11%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Pacira BioSciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -17.62%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -9.06%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PCRX

What 8 Analyst Ratings Have To Say About Pacira BioSciences

Financial Institutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FISI#NASDAQ">FISI</a>) reported quarterly adjusted earnings of $0.55 per share which missed the analyst consensus estimate of $0.56. The company reported quarterly sales of $41.63 million which missed the analyst consensus estimate of $42.36 million by 1.71 percent. This is a 4.38 percent increase over sales of $39.89 million the same period last year. Adjusted earnings exclude loss on investment securities of $100.1M or $75M after-tax due to previously disclosed securities portfolio restructurings.

Earnings Misses

FISI

Financial Institutions Q4 Adj EPS $0.55 miss $0.56 Estimate, Sales $41.63M Miss $42.36M Estimate. Adjusted EPS excludes loss on investment securities of $100.1M or $75M after-tax due to previously disclosed securities portfolio restructurings.

Dividends

Walgreens Boots Alliance Says Its Cash Needs Over Next Several Years, Including With Respect To Litigation And Debt Refinancing, Were Important Considerations To Suspend Dividend

Donaldson's advanced air filter technology is set to be featured in the next-generation Freightliner SuperTruck III, further solidifying its position at the forefront of hydrogen fuel cell innovation.

Donaldson Enters Partnership With Daimler Truck North America On Hydrogen Fuel Cell Project

Tigress Financial analyst Ivan Feinseth maintains Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Buy and maintains $55 price target.

Tigress Financial Maintains Buy on Verizon Communications, Maintains $55 Price Target

Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) just disclosed its Q2 earnings on Thursday, January 30, 2025 at 04:05 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Atlassian beat estimated earnings by 26.0%, reporting an EPS of $0.96 versus an estimate of $0.76.
Revenue was up $226.00 million from the same period last year.
<h3>Historical Earnings Summary</h3>
In the previous quarter, the company beat on EPS by $0.13, resulting in a 19.0% increase change in the share price the following day.
Here's a look at Atlassian's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.64</td>
<td>0.61</td>
<td>0.62</td>
<td>0.62</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.77</td>
<td>0.66</td>
<td>0.89</td>
<td>0.73</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.15B</td>
<td>1.13B</td>
<td>1.10B</td>
<td>1.02B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.19B</td>
<td>1.13B</td>
<td>1.19B</td>
<td>1.06B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Atlassian <a href="https://www.benzinga.com/quote/TEAM/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TEAM

Atlassian Q2 Earnings Assessment

Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) announced its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Bancorp beat estimated earnings by 2.0%, reporting an EPS of $1.15 versus an estimate of $1.13.
Revenue was up $2.14 million from the same period last year.
<h3>Previous Earnings Records</h3>
During the previous quarter, the company missed on EPS by $0.08, leading to a 14.000000000000002% drop share price change the next day.
Here's a look at Bancorp's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.12</td>
<td>1.07</td>
<td>1.05</td>
<td>0.95</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.04</td>
<td>1.07</td>
<td>1.06</td>
<td>0.95</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>99.31M</td>
<td>96.41M</td>
<td>116.51M</td>
<td>90.65M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>93.73M</td>
<td>93.80M</td>
<td>94.42M</td>
<td>92.16M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Bancorp management provided guidance for FY 2025, expecting earnings between $5.25 and $5.25 per share.
To track all earnings releases for Bancorp <a href="https://www.benzinga.com/quote/TBBK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TBBK

Bancorp Q4 Earnings Assessment

Standex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) released its Q2 earnings on Thursday, January 30, 2025 at 04:01 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Standex International beat estimated earnings by 14.000000000000002%, reporting an EPS of $1.91 versus an estimate of $1.67.
Revenue was up $11.41 million from the same period last year.
<h3>Past Earnings Performance</h3>
In the previous quarter, the company beat on EPS by $0.01, resulting in a 4.0% increase change in the share price the following day.
Here's a look at Standex International's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.70</td>
<td>1.72</td>
<td>1.67</td>
<td>1.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.71</td>
<td>1.76</td>
<td>1.75</td>
<td>1.78</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>181.39M</td>
<td>181.29M</td>
<td>180.14M</td>
<td>182.52M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>170.46M</td>
<td>180.19M</td>
<td>177.27M</td>
<td>178.40M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Standex International <a href="https://www.benzinga.com/quote/SXI/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Standex International Earnings Report: Q2 Overview

The Q4 earnings report for Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) was released on Thursday, January 30, 2025 at 04:15 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.
Revenue was up $38.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat on EPS by $0.12 which was followed by a 4.0% drop in the share price the next day.
Here's a look at Eastman Chemical's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.
To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Eastman Chemical Q4 Earnings

Walgreens Boots Alliance Suspends Quarterly Dividend

The earnings results for Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) for Q4 were made public on Thursday, January 30, 2025 at 04:15 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Arthur J. Gallagher beat estimated earnings by 5.0%, reporting an EPS of $2.13 versus an estimate of $2.03.
Revenue was up $284.00 million from the same period last year.
<h3>Historical Earnings Summary</h3>
Last quarter the company missed on EPS by $0.01 which was followed by a 2.0% drop in the share price the next day.
Here's a look at Arthur J. Gallagher's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.27</td>
<td>2.24</td>
<td>3.41</td>
<td>1.85</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.26</td>
<td>2.26</td>
<td>3.49</td>
<td>1.85</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>2.78B</td>
<td>2.76B</td>
<td>3.18B</td>
<td>2.36B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>2.81B</td>
<td>2.77B</td>
<td>3.26B</td>
<td>2.43B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Arthur J. Gallagher <a href="https://www.benzinga.com/quote/AJG/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Arthur J. Gallagher Q4 Earnings

The earnings results for Adtalem Glb Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) for Q2 were made public on Thursday, January 30, 2025 at 04:15 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Adtalem Glb Education beat estimated earnings by 32.0%, reporting an EPS of $1.81 versus an estimate of $1.37.
Revenue was up $54.49 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company beat on EPS by $0.16 in the previous quarter, leading to a 10.0% increase share price change the next day.
Here's a look at Adtalem Glb Education's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.13</td>
<td>1.28</td>
<td>1.16</td>
<td>0.98</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.29</td>
<td>1.37</td>
<td>1.50</td>
<td>1.23</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>397.70M</td>
<td>398.63M</td>
<td>391.70M</td>
<td>372.79M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>417.40M</td>
<td>409.91M</td>
<td>412.66M</td>
<td>393.24M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Adtalem Glb Education management provided guidance for FY 2025, expecting earnings between $6.1 and $6.3 per share.
To track all earnings releases for Adtalem Glb Education <a href="https://www.benzinga.com/quote/ATGE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Adtalem Global Education Inc. Common Stock

ATGE

Insights into Adtalem Glb Education Q2 Earnings

An update from HeartCore Enterprises, Inc. ( ($HTCR) ) is now available. HeartCore Enterprises has transitioned its CMS platform to a SaaS model, u...

HeartCore Enterprises Shifts CMS to SaaS Model

HeartCore Enterprise announced that it has received written notice from the Nasdaq Stock Market that the Company demonstrated compliance with the $...

HeartCore Enterprises regains compliance with Nasdaq listing requirements

HeartCore GAAP EPS of $0.53 beats by $0.10, revenue of $17.85M beats by $0.27M

HeartCore Enterprises, Inc. ( ($HTCR) ) has issued an announcement. HeartCore Enterprises, Inc. will unveil its investor presentation starting Nove...

HeartCore Enterprises to Unveil Investor Presentation

Innovative solutions are revolutionizing sectors around the globe and bringing in a new industrial revolution. In this thriving landscape, should PTC Inc. (PTC), with its industry-leading software offerings, be on your radar? Read on… Industries worldwide are going through a digital transformation fueled by transformative capabilities of Artificial Intelligence (AI), global connectivity, advanced analytics, automation, and advanced manufacturing technology. The transformation has aptly been named <a href="https://www.weforum.org/about/the-fourth-industrial-revolution-by-klaus-schwab/">the Fourth Industrial Revolution</a> or Industry 4.0, shaping a new era of innovation and making massive contributions to the economy itself.
Amid this transformation, PTC Inc. (<a href="https://stocknews.com/stock/PTC/">PTC</a>) stands out as a pioneer in the aforementioned fields owing to its wide range of software solutions that are fueling the engine of Industry 4.0. The company offers <a href="https://www.ptc.com/en/technologies/cad">Computer-aided design</a> (CAD) software solutions that digitally create 2D drawings and 3D models of real-world products before they are even manufactured, enhancing product development and R&amp;D processes.
Moreover, PTC also offers <a href="https://www.ptc.com/en/technologies/plm">Product lifecycle management</a> (PLM) solutions to streamline product development by enabling geographically dispersed, multidisciplinary teams to strategically collaborate with partners and customers using trusted, up-to-date product information.
That being said, PTC's stock climbed 1.8% over the past six months and gained 5% over the past year, closing the last trading session at $184.50.
Now, let us delve deeper into the factors that could shape PTC's performance in the near future.
Recent Developments
On December 3, PTC <a href="https://investor.ptc.com/resources/news/news-details/2024/PTC-Partners-with-Microsoft-and-Volkswagen-Group-to-Develop-Codebeamer-Generative-AI-Copilot/default.aspx">announced a partnership</a> with Microsoft Corporation (<a href="https://stocknews.com/stock/MSFT/">MSFT</a>) and Volkswagen AG (<a href="https://stocknews.com/stock/VWAGY/">VWAGY</a>) to develop a GenAI copilot based on the PTC Codebeamer&#xAE; application lifecycle management (ALM) solution. Codebeamer Copilot is aimed at supporting software development in physical products by making creation and product requirements more efficient.
The partnership is set to amplify the value of Codebeamer by embedding GenAI with Microsoft Azure AI capabilities and strengthen PTC's position in the booming AI market.
On September 25, PTC entered into a <a href="https://investor.ptc.com/resources/news/news-details/2024/PTC-Announces-Strategic-Collaboration-Agreement-with-AWS-to-Help-Companies-Design-Products-Faster-and-Easier-with-Onshape/default.aspx">strategic collaboration agreement</a> with Amazon Web Services (AWS) aimed at accelerating the growth of its Onshape&#xAE; cloud-native computer-aided design (CAD) and product data management (PDM) solution.
The collaboration could enhance the company's Onshape solution, customer adoption programs, and AI initiatives, resulting in strong user growth.
Sound Historical Growth
Over the past five years, PTC has demonstrated consistent growth across key financial metrics. Its revenue grew at a CAGR of 12.9%, while EBITDA rose at a 29.3% CAGR. Moreover, operational income (EBIT) and total assets expanded at a CAGR of 38.2% and 19.1%, respectively.
Strong Financials
For the fiscal 2024 fourth quarter that ended September 30, PTC's total revenue increased 14.6% year-over-year to $626.55 million. Its non-GAAP gross margin rose 18.6% from the year-ago value to $528.84 million. The company's non-GAAP operating income grew 37.8% from the prior year's quarter to $276.56 million.
Additionally, non-GAAP net income and non-GAAP EPS increased 29.1% and 28.3% year-over-year to $186.06 million and $1.54, respectively. As of September 30, 2024, PTC's total assets amounted to $6.38 billion compared to $6.29 billion on September 30, 2023.
Favorable Analyst Estimates
Analysts expect PTC's revenue for the fiscal 2025 first quarter ending December 2024 to increase marginally year-over-year to $555.51 million. Its EPS is expected to come in at $0.90 for the same period. Moreover, the company exceeded the consensus EPS estimates in each of the four trailing quarters, which is noteworthy.
For the full fiscal year ending September 2025, PTC's revenue and EPS are expected to rise 10.9% and 16.1% from the previous year, reaching $2.55 billion and $5.90, respectively.
High Profitability
PTC's trailing-12-month <a href="https://www.investopedia.com/terms/g/gross_profit_margin.asp">gross profit margin</a> of 80.65% is 58.2% higher than the industry average of 50.98%. Its trailing-12-month EBITDA margin stands at 30.42%, 193.1% higher than the industry average of 10.38%.
In addition, the company boasts a trailing-12-month net income margin of 16.37%, which is 333.7% higher than the sector average of 3.78%. Also, the stock's trailing-12-month ROCE of 12.78% outperforms the industry average of 4.36% by 192.7%.
POWR Ratings Reflects Optimism
PTC's sound fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
PTC has a B grade for Quality, supported by profitability measures that exceed industry benchmarks. Its B grade for Momentum further underscores strong technical performance, with the stock trading above its 100-day moving average of $183.83 and 200-day moving average of $181.78.
Furthermore, PTC has a B grade for Growth, which is in line with its impressive historical growth. Within the B-rated <a href="https://stocknews.com/category/software-application/">Software - Application</a> industry, PTC is ranked #39 out of 125 stocks.
Beyond what is stated above, we have also given PTC grades for Stability, Sentiment, and Value. Get all PTC ratings <a href="https://stocknews.com/stock/PTC/">here</a>.
Bottom Line
PTC has established itself as an industry leader for more than 30 years through its software product offerings that have contributed immensely to driving digital transformation across different industries.
With its cutting-edge technological innovations, robust financials, impressive growth metrics, and sustained profitability, PTC stands out as a compelling investment opportunity. Its stable momentum further underscores why now might be the perfect time to consider adding PTC to one's portfolio.
How Does PTC Inc. (PTC) Stack Up Against Its Peers?
Although PTC's near-term outlook appears sound, it may be worthwhile to explore its industry peers, who also exhibit even stronger POWR Ratings. So, consider these A (Strong Buy) rated stocks from the Software - Application industry:
Progress Software Corporation (<a href="https://stocknews.com/stock/PRGS/">PRGS</a>)
IBEX Limited (<a href="https://stocknews.com/stock/IBEX/">IBEX</a>)
Heartcore Enterprises, Inc. (<a href="https://stocknews.com/stock/HTCR/">HTCR</a>)
To explore more A or B-rated Software - Application stocks, <a href="https://stocknews.com/category/software-application/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
PTC shares were unchanged in premarket trading Monday. Year-to-date, PTC has gained 5.45%, versus a 26.79% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/ptc-prgs-ibex-htcr-msft-vwagy-should-ptc-inc-be-on-your-radar-as-a-leader/>Should PTC Inc. Be on Your Radar as a Leader in Digital Transformation?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Should PTC Inc. Be on Your Radar as a Leader in Digital Transformation?

Driven by the increasing popularity of online education by institutions and organizations, the e-learning industry is seeing substantial growth. In this thriving environment, is Docebo (DCBO) a smart investment for investors looking to capitalize on the industry's growth? Read more… The e-learning industry has surged in recent years, driven by rising demand for remote learning, upskilling, and the widespread adoption of digital platforms in education and corporate sectors. Additionally, increased internet access and faster connectivity are further fueling the growth of digital education worldwide.
The growing availability of mobile-based learning apps and higher education institutions integrating e-learning modules to offer hybrid and distance-learning programs are enhancing the prospects of the industry. That said, the global e-learning services market is forecasted to reach $842.60 million by 2030, growing at an impressive <a href="https://www.grandviewresearch.com/industry-analysis/e-learning-services-market">CAGR of 19%</a>.
Amid this growth, Docebo Inc. (<a href="https://stocknews.com/stock/DCBO/">DCBO</a>) stands out as a leading figure in the aforementioned industry, offering an artificial intelligence (AI)-powered learning platform for organizations and individuals. DCBO's shares have surged 10.4% over the past six months, closing the last trading session at $42.87.
Now, let us dive deeper into the factors that could shape DCBO's performance in the near future.
Recent Developments
On November 11, 2024, DCBO <a href="https://docebo.inc/news/news-details/2024/Docebo-and-Deloitte-Forge-Strategic-Alliance-Enabling-Enterprises-to-Evolve-Into-High-Impact-Learning-Organizations/default.aspx">announced a strategic alliance</a> with Deloitte to aid mid-size and large organizations in building robust, growth-focused learning ecosystems. This collaboration combines DCBO's cutting-edge learning technology with Deloitte's consulting and implementation knowledge and could enhance the company's market presence amid the corporate space.
On October 2, DCBO partnered with TEDAI for the TEDAI Vienna event, serving as <a href="https://docebo.inc/news/news-details/2024/Docebo-Partners-with-TEDAI-Vienna-as-The-Business-Learning-Partner-for-Europes-Inaugural-AI-Conference/default.aspx">the business learning partner</a>. DCBO played a key role in showcasing how enterprises can harness AI to transform workplace learning and development. The collaboration is a testament to the company's commitment to reshape the future of work through AI.
Sound Financials
For the fiscal 2024 third quarter that ended on September 30, DCBO's revenue increased 19.2% year-over-year to $55.43 million. Its <a href="https://www.investopedia.com/terms/o/operatingincome.asp">operating income</a> grew 51.7% from the year-ago value to $4.72 million.
Additionally, the company's adjusted net income and adjusted EPS rose 66.7% and 80% from the prior year's quarter to $8.26 million and $0.27, respectively. As of September 30, 2024, DCBO's cash and cash equivalents amounted to $82.03 million, compared to $71.95 million on December 31, 2023.
Optimistic Analyst Estimates
Analysts predict DCBO's revenue and EPS for the fiscal 2025 first-quarter ending in March to increase 13.9% and 20.7% year-over-year to $58.52 million and $0.28, respectively. In addition, the company exceeded the consensus revenue and EPS estimates in each of the four trailing quarters, which is impressive.
Looking at the full fiscal year that ended December 2025, DCBO's revenue and EPS are expected to rise 14.3% and 30.2% year-over-year to $247.11 million and $1.31, respectively.
High Profitability
DCBO's trailing-12-month gross profit margin of 80.85% is 60% higher than the industry average of 50.55%. Its trailing-12-month net income margin stands at 8.63%, 126.9% higher than the industry average of 3.80%.
In addition, the company boasts a trailing-12-month levered FCF margin of 14.92%, which is 32.7% higher than the sector average of 11.24%. Also, the stock's trailing-12-month ROCE of 19.97% outperforms the industry average of 4.22% by 373.5%.
POWR Ratings Reflects Optimism
DCBO's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
DCBO has an A grade for Sentiment, which is in line with the optimistic analyst estimates. Plus, the stock holds a B grade for Quality, supported by profitability measures that exceeded industry benchmarks.
Within the B-rated <a href="https://stocknews.com/category/software-application/">Software - Application</a> industry, DCBO is ranked #5 out of 124 stocks. Beyond what is stated above, we have also given DCBO grades for Momentum, Value, Stability, and Growth. Get all DCBO ratings <a href="https://stocknews.com/stock/DCBO/">here</a>.
Bottom Line
DCBO has established itself as a titan in the e-learning industry with cutting-edge AI-powered learning offerings that have played an important role in training internal and external workforces, partners, and customers. The company's growth prospects seem robust as the industry expands.
Given DCBO's impressive analyst estimates, high profitability, and strategic industry position, now could be the ideal time to consider adding the stock to your portfolio.
How Does Docebo Inc. (DCBO) Stack Up Against Its Peers?
Although DCBO's near-term outlook appears sound, it may be worthwhile to explore its industry peers, who also exhibit strong POWR Ratings. So, consider these A (Strong Buy) rated stocks from the Software - Application industry:
Progress Software Corporation (<a href="https://stocknews.com/stock/PRGS/">PRGS</a>)
IBEX Ltd. (<a href="https://stocknews.com/stock/IBEX/">IBEX</a>)
Heartcore Enterprises Inc. (<a href="https://stocknews.com/stock/HTCR/">HTCR</a>)
To explore more A or B-rated Software - Application stocks, <a href="https://stocknews.com/category/software-application/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
DCBO shares were unchanged in premarket trading Friday. Year-to-date, DCBO has declined -4.24%, versus a 0.95% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aritra_Gangopadhyay</h2> <img src='https:/wp-content/uploads/2025/01/Aritra_Gangopadhyay.png' style="float:left; padding:5px;width:125px;">Aritra is a financial journalist dedicated to breaking down complex financial topics into simple, actionable insights. Holding a Master's degree in Economics, he uses his analytical expertise to help investors uncover unique opportunities for long-term success.<a href="https://stocknews.com/authors/?author=aritra-gangopadhyay">More...</a>The post <a href=https://stocknews.com/news/dcbo-prgs-ibex-htcr-is-docebo-a-smart-investment-in-the-e-learning-industry/>Is Docebo a Smart Investment in the E-Learning Industry?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Comments

HeartCore Enterprises

Noticias

Últimas noticias sobre HeartCore Enterprises (NASDAQ:HTCR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL